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patients can improve prognosis and reduce the burden of cardiovascular mortality.
Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy
(LIPIGEN Study).
Methods: We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network
criteria. We performed a parallel sequencing of the major candidate genes for monogenic hypercholesterolemia (LDLR, APOB, PCSK9,
APOE, LDLRAP1, STAP1).
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than 94% of patients carried pathogenic variants in LDLR gene, 27 of which were novel. Pathogenic variants in APOB and PCSK9 were
exceedingly rare. We found 4 true homozygotes and 5 putative compound heterozygotes for pathogenic variants in LDLR gene, as well as 5
double heterozygotes for LDLR/APOB pathogenic variants. Two patients were homozygous for pathogenic variants in LDLRAP1 gene
resulting in autosomal recessive hypercholesterolemia. One patient was found to be heterozygous for the ApoE variant p.(Leu167del),
known to confer an FH phenotype.
Conclusions: This study shows the molecular characteristics of the FH patients identified in Italy over the last two years. Full phenotypic
characterization of these patients and cascade screening of family members is now in progress.
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At present three canonical genes underlie familial
hypercholesterolemia (FH) with co-dominant transmission
(autosomal dominant hypercholesterolemia, ADH): LDLR
(ADH-type 1), APOB (ADH-type 2) and PCSK9 (ADH-
type 3). Other genes, like STAP1 (ADH-type 4) and APOE
(ADH-type 5) have been implicated in some rare forms of
FH with dominant transmission [1e3]. In all molecular
surveys performed so far in different cohorts of FH patients,
mutations in LDLR gene were found in more than 85e90%
of FH cases. More than 1700 mutations of this gene have
been reported so far and annotated in the UCL database [4].
Few mutations in APOB underlie ADH-2, two of which are
predominant [5]. Gain-of-function (GOF) mutations of
PCSK9 causing FH are exceedingly rare [6]. Only a single
mutation in APOE gene [p.(Leu167del)] was found to be
the cause of a dominant FH phenotype [3]. FH-like
phenotypes with a recessive transmission are extremely
rare. This group of disorders includes the classic autosomal
recessive hypercholesterolemia (ARH) caused by mutations
in LDLRAP1 gene [7], sitosterolemia caused by mutations
in ABCG5/ABCG8 genes [8], and lysosomal acid lipase
deficiency (LAL-D) due to mutations in LIPA gene [9].
With regard to the prevalence of FH with co-dominant
transmission (ADH), recent data based on the determina-
tion of the carrier status of pathogenic variants in LDLR and
APOB genes indicate a frequency of 1:217 for heterozy-
gotes in the general population [10]. An extensive molec-
ular study conducted in the Netherlands in genotyped FH
patients indicated a prevalence of heterozygous ADH of
1:244 individuals and a prevalence of homozygous FH of
1:300,000 [11]. Several reports have shown that a variable
percentage (20e40%) of patients with the clinical diagnosis
of heterozygous FH do not carry mutations in the candidate
genes mentioned above [12]. Some of these patients were
found to carry a burden of LDL-cholesterol (LDL-C)
increasing gene variants which cumulatively raise LDL-C
levels into the heterozygous FH range [12,13]. However,
there are patients in whom the polygenic effect does not
explain the high LDL-C levels, indicating the possible
presence of other genes yet to be identified [13].
In a previous study [14] we have characterized the
molecular bases of ADH in a cohort of Italian FH patients
attending three Lipid Clinics in Italy and performed
a systematic analysis of the clinical features of mutation-
positive ADH patients. This study paved the way for the
construction of the LIPIGEN network, as an integrated
network aimed at the early clinical/molecular identification
and treatment of patients with genetic dyslipidemias (Ref.
Averna M. et al. in this issue). The first aim of LIPIGEN
was to improve the identification and molecular charac-
terization of FH patients thanks to a collaboration among
a large number of Lipid Clinics distributed over the entire
country. In this brief report we show the results of the
molecular characterization of more than 1000 patientscarried out during the first two years of activity of the
LIPIGEN network.
2. Materials and methods2.1. SubjectsFor this analysis, 1592 unrelated patients from 20
outpatient clinics with clinical diagnosis of FH and a Dutch
Lipid Clinic Network (DLCN) score  6 were genetically
tested for the presence of variants in FH causing genes.
Informed consent was obtained from all subjects. The
project was approved by the Ethics Committees of each
participating institution.2.2. DNA isolation and sequencingGenomic DNA was extracted using the Flexigene DNA
kit (Qiagen, Milan, Italy) according to the manufacturer’s
instructions. Appropriate primers were used for the PCR
amplification of exons and exon-intron junctions of the
following genes: LDLR (18 exons), PCSK9 (12 exons) and
LDLRAP1 (9 exons), as well as regions in APOB exons 26
and 29 involved in the binding to LDLR, exon 4 of APOE
gene and STAP1 gene (9 exons). As internal control,
regions of chromosome 21 were amplified. Fifty-eight
regions of interest (20 Kb) were amplified from genomic
DNA in five different multiplex PCR reactions. A second
amplification was then performed in order to include an 8nt
index sequence used for sample identification, as well as
the adaptors used for sequencing on MiSeq (Illumina)
equipment. Before sequencing, purified amplified samples
were quantified and diluted to the same concentration. The
genetic analysis, including the complete sequence of genes,
was performed by Next Generation Sequencing (see above)
followed by the Sanger sequence to confirm the presence of
the identified variant. Multiplex Ligation-dependent Probe
Amplification (MLPA) analysis was used to detect copy
number variations.
In silico analysis of missense mutations was performed
using PolyPhen-2 HumDiv and Hum Var (http://genetics.
bwh.harvard.edu/pph2/), SIFT Human Protein (http://sift.
jcvi.org/) and Mutation Taster (www.mutationtaster.org/).
The potential effect of an intronic variant on pre-mRNA
splicing was assessed by Human Splicing Finder (http://
www.umd.be/HSF3/HSF.html), NetGene2 (http://www.cbs.
dtu.dk/sevices/NetGene2/), BDGP Splice Site prediction
(http://www.fruitfly.org/seq_tools/splice.html), Splice Port
(http://spliceport.cbcb.umd.edu/) and Splice Site Score Cal-
culation (http://rulai.cshl.edu/new_alt_exon_db2/HTML/
score.html).
3. Results
In a series of 1592 FH index subjects, 1076 (67.6%)
were found to carry at least one variant of the investigated
19A. Pirillo et al. / Atherosclerosis Supplements 29 (2017) 17e24genes. Most of them (1016 subjects, 94.4%) carried at least
one variant in the LDLR gene; a total number of 213
variants of LDLR gene have been identified. More than
90% of patients were carriers of definite pathogenic/likely
pathogenic LDLR gene variants. Most LDLR variants were
single nucleotide substitutions, mainly in the coding
sequence. Large gene deletions were found in 53 subjects,
whereas single nucleotide or minute deletions were found
in 36 and 45 subjects respectively. Single nucleotide or
minute duplications were found in 21 subjects.
The most common mutations in LDLR gene were
[c.1646G>A, p.(Gly549Asp)] (107/1016), [c.662A>G,
p.(Asp221Gly)] (84/1016), [c.1775G>A, p.(Gly592Glu)]
(45/1016) and [c.1567G>A, p.(Val523Met)] (44/1016), all
previously reported in Italian FH patients [14]. Thirty-two
LDLR gene variants found in this survey had not been re-
ported previously. In silico analysis indicated that 27 ofTable 1
New LDLR gene variants.
Gene variant (c.DNA) Type of variant Clinical
c.-97G>A Promoter Reduced
c.3G>A Aa change Pathogen
c.38_58del21 Deletion Pathogen
c.68-?_190þ?dup Exon 2 duplication Pathogen
c.94T>C Aa change Pathogen
c.191-?_2311þ?dup Exons 3e15 duplication Pathogen
c.246delC Deletion Pathogen
c.313þ4_313þ16del13 Affects donor splice site Pathogen
c.314-?_2583þ?del Exons 4e18 deletion Pathogen
c.316_328delCCCAAGACGTGCT Deletion Pathogen
c.363C>A Nonsense Pathogen
c.620_626delGCGAGTG Deletion Pathogen
c.641G>A Aa change Pathogen
C.688A>G Aa change Unlikely
c.698T>C Aa change Unlikely
c.906C>A Aa change Pathogen
c.920A>C Aa change Pathogen
c.926C>A Aa change Pathogen
c.1037delT Deletion Pathogen
c.1061-1G>T Acceptor splice site broken Pathogen
(skipping
c.1171delG Deletion Pathogen
c.1413_1414delAGinsGGACAT Insertion/deletion Pathogen
c.1470G>T Aa change Pathogen
c.1491delT Deletion Pathogen
c.1498delG Deletion Pathogen
c.1587-?_2583þ?del Exons 11e18 deletion Pathogen
c.1686G>T Aa change Pathogen
c.1943_1944delCCinsG Deletion Pathogen
c.2120A>C Aa change Pathogen
c.2257C>G Aa change Unlikely
c.2311_2311þ15del16 Donor splice site broken Pathogen
c.2299A>G Aa change Possibly
In silico analysis of missense mutations was performed using PolyPhen-2 Hum
Protein (http://sift.jcvi.org/) and Mutation Taster (www.mutationtaster.org/). The p
Human Splicing Finder (http://www.umd.be/HSF3/HSF.html), NetGene2 (http://
www.fruitfly.org/seq_tools/splice.html), Splice Port (http://spliceport.cbcb.umd
exon_db2/HTML/score.html).them could be regarded as pathogenic/likely pathogenic
variants (Table 1).
Pathogenic APOB gene variants located in exon 26
(Table 2) were found in 34 subjects.
Four PCSK9 variants were found in 36 subjects (Table
3). The most common were: i) the [c.137G>T,
p.(Arg46Leu)] variant (found in 15 subjects), which is
a known loss-of-function variant (LOF) associated with
reduced LDL-C levels, and ii) c.60_65dupGCTGCT
[p.(Leu21tri)] (in 17 subjects), which is regarded to be
a GOF variant and a possible cause of FH [6].
Twelve LDLRAP1 gene variants were identified in 18
subjects. Five variants were pathogenic, 4 unlikely patho-
genic and 3 of unknown significance (Table 4). Among the
identified LDLRAP1 variants, 4 have not been reported
previously. However, only 1 of these new variants can be
assumed to be pathogenic.significance Protein change
transcription?
ic p.(Met1Ile)
ic? p.(Ala13_Ala19del)
ic p.(Gly24_Leu64dup)
ic p.(Phe32Leu)
ic p.[Ala771Val; Ser65_Ala771dup]
ic p.(Cys82*)
ic (new donor splice site in exon 3) p.(Arg88Serfs*25)
ic p.0
ic p.(Lys107Argfs*95)
ic p.(Cys121*)
ic p.(Gly207Alafs*56)
ic p.(Trp214*)
pathogenic p.(Asn230Asp)
pathogenic p.(Val233Ala)
ic p.(Cys302*)
ic p.(Asp307Ala)
ic p.(Pro309His)
ic p.(Leu346Argfs*24)
ic
Exon 8)
ic p.(Ala391Profs*22)
ic p.(Gln474Hisfs*63)
ic p.(Trp490Cys)
ic p.(Val498Serfs*9)
ic p.(Val500Leufs*7)
ic p.0
ic p.(Trp562Cys)
ic p.(Ser48Cysfs*17)
ic p.(Asp707Ala)
pathogenic p.(Pro753Ala)
ic
pathogenic p.(Met767Val)
Div and Hum Var (http://genetics.bwh.harvard.edu/pph2/), SIFT Human
otential effect of an intronic variant on pre-mRNA splicing was assessed by
www.cbs.dtu.dk/sevices/NetGene2/), BDGP Splice Site prediction (http://
.edu/) and Splice Site Score Calculation (http://rulai.cshl.edu/new_alt_
Table 2
Pathogenic variants in APOB gene.
Gene variant
(c.DNA)
Type of variant Clinical significance Protein change
c.10579C>T Aa change Pathogenic p.(Arg3527Trp)
c.10580G>A Aa change Pathogenic p.(Arg3527Gln)
c.10672C>T Aa change Pathogenic p.(Arg3558Cys)
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gene (Table 5). Only 8 of these subjects carried five
combinations of two variants with pathogenic effect. No
formal family study was performed to assess whether theTable 5
Heterozygous carriers of two LDLR gene variants.
LDLR gene
1st variant
Protein Clinical significance
c.1587-?_2583þ?del (2 subjects) p.0 Pathogenic
c.68-?_1845þ?del p.(Val23Glyfs*29) Pathogenic
c.1775G>A p.(Gly592Glu) Pathogenic
c.2072C>T p.(Ser691Leu) NEW Pathogenic
c.352G>T p.(Asp118Tyr) Pathogenic
c.58G>A p.(Gly20Arg) Unknown significan
c.58G>A p.(Gly20Arg) Unknown significan
c.662A>G p.(Asp221Gly) Pathogenic
c.665G>A p.(Cys222Tyr) Pathogenic
c.858C>A p.(Ser286Arg) Pathogenic
c.898A>G (4 subjects) p.(Arg300Gly) Pathogenic
c.304C>T p.(Gln102*) Pathogenic
c.418G>T p.(Glu140*) Pathogenic
In silico analysis of missense mutations was performed using PolyPhen-2 Hum
Protein (http://sift.jcvi.org/) and Mutation Taster (www.mutationtaster.org/).
Table 4
Variants in LDLRAP1 gene.
Gene variant (c.DNA) Type of variant
c.-17_-12dupGGCGGC e
c.65G>A Nonsense
c.89-1G>C Acceptor splice site broken
c.457A>G NEW Aa change
c.569G>C Aa change
c.603dupC Duplication
c.605C>A Aa change
c.653C>T Aa change
c.748-2A>G NEW Acceptor splice site broken
c.811G>A Aa change
c.888C>G NEW Aa change
c.896G>A NEW Aa change
Table 3
Variants in PCSK9 gene.
Gene variant (c.DNA) Type of variant
c.137G>T Aa change
c.-331C>Ab Promoter
c.60_65dupGCTGCT (c.61_63triCTG) Aa change
c.1327G>A Aa change
a Dron JS, Hegele RA. Curr Opin Lipidol. 2017; 28: 161e9.
b Previously reported as -332C>A by Blesa S et al. J Clin Endocrinol Metabtwo variants were on the same or on different alleles.
However it can be reasonable assumed that carriers of two
pathogenic variants (8 patients) might be compound
heterozygotes.
Nineteen subjects were double heterozygotes for LDLR/
PCSK9 variants (Table 6). However only seven of these
subjects were found to carry a putative or definite GOF
variant of PCSK9 expected to contribute to the FH
phenotype. Five subjects were double heterozygotes for
pathogenic variants of LDLR and APOB genes (Table 7).
We also identified 5 double heterozygotes for LDLR/
LDLRAP1 variants; all of them carried a pathogenicLDLR gene
2nd variant
Protein Clinical significance
c.1336C>G p.(Leu446Val) Unlikely pathogenic
c.2257C>G p.(Pro753Ala) NEW Unlikely pathogenic
c.2299A>G p.(Met767Val) NEW Unlikely pathogenic
c.38_58del21 p.(Ala13_Ala19del) NEW Unknown significance
c.1211C>T p.(Thr404Ile) Pathogenic
ce c.1474G>A p.(Asp492Asn) Pathogenic
ce c.1257C>G p.(Try419*) Pathogenic
c.698T>C p.(Val233Ala) NEW Unlikely pathogenic
c.815A>C p.(Asn272Thr) Unknown significance
c.2054C>T p.(Pro685Leu) Pathogenic
c.907C>T p.(Arg303Trp) Pathogenic
c.718G>A p.(Glu240Lys) Pathogenic
c.352G>T p.(Asp118Tyr) Pathogenic
Div and Hum Var (http://genetics.bwh.harvard.edu/pph2/), SIFT Human
Clinical significance Protein change
Unknown significance
Pathogenic p.(Trp22*)
Pathogenic p.(Lys30Thrfs*3)
Unknown significance p.(Met153Va)
Unlikely pathogenic p.(Gly190Ala)
Pathogenic p.(Ser202Leufs*19)
Pathogenic p.(Ser202Tyr)
Unlikely pathogenic p.(Thr218Ile)
Pathogenic p.(Glu250Glyfs*4)
Unknown significance p.(Val271Ile)
Unlikely pathogenic p.(Asp296Glu)
Unlikely pathogenic p.(Gly299Asp)
Clinical significance Protein change
LOF varianta p.(Arg46Leu)
GOF variant a; 2,5-fold increase transcription
GOF varianta p.(Leu21tri)
Unlikely pathogenic p.(Ala443Thr)
2008; 93: 3577e83.
Table 6
Double heterozygotes for LDLR and PCSK9 gene variants.
LDLR gene variant Protein Clinical significance PCSK9 gene variant Protein Clinical significance
c.1187-?_2140þ?dup p.(Gly396_Thr713dup) Pathogenic c.1327G>A p.(Ala443Thr) Unlikely pathogenic
c.1246C>T (2 subjects) p.(Arg416Trp) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.1257C>G p.(Try419*) Pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
c.1257C>G p.(Try419*) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.126C>A p.(Try42*) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.1646G>A p.(Gly549Asp) Pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
c.1783C>T p.(Arg595Trp) Pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
c.1846-?_2583þ?del (2
subjects)
p.0 Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.2215C>T p.(Gln739*) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.2312-3C>A p.(Ala771_Ile796del) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.352G>T p.(Asp118Tyr) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.373C>T (HO) p.(Gln125*) Pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
c.418G>T p.(Glu140*) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.418G>T p.(Glu140*) Pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
c.662A>G p.(Asp221Gly) Pathogenic C.137G>T p.(Arg46Leu) LOF variant
c.788A>G p.(Asp263Gly) NEW Pathogenic c.-331C>A 2,5-fold increase
transcription
GOF variant
c.1547G>A p.(Gly516Asp) Unlikely pathogenic c.60_65dupGCTGCT
(c.61_63triCTG)
p.(Leu21tri) GOF variant
GOF: gain-of-function; LOF: loss-of-function.
In silico analysis of missense mutations was performed using PolyPhen-2 HumDiv and Hum Var (http://genetics.bwh.harvard.edu/pph2/), SIFT Human
Protein (http://sift.jcvi.org/) and Mutation Taster (www.mutationtaster.org).
Table 7
Double heterozygotes for LDLR and APOB gene variants.
LDLR gene variant Protein Clinical significance APOB gene variant Protein Clinical significance
c.1470G>T p.(Trp490Cys) NEW Pathogenic c.10579C>T p.(Arg3527Trp) Pathogenic
c.1735G>A p.(Asp579Asn) Pathogenic c.10580G>A p.(Arg3527Gln) Pathogenic
c.662A>G p.(Asp221Gly) Pathogenic c.10580G>A p.(Arg3527Gln) Pathogenic
c.662A>G p.(Asp221Gly) Pathogenic c.10580G>A p.(Arg3527Gln) Pathogenic
c.662A>G p.(Asp221Gly) Pathogenic c.10580G>A p.(Arg3527Gln) Pathogenic
Table 8
Double heterozygotes for LDLR and LDLRAP1 gene variants.
LDLR gene variant Protein Clinical significance LDLRAP1 gene variant Protein Clinical significance
c.858C>A p.(Ser286Arg) Pathogenic c.457A>G p.(Met153Val) Unknown significance
c.38_58del21þ
c.2072C>T
p.(Ala13_Ala19del)þ
p.(Ser691Leu)
Pathogenic c.653C>T p.(Thr218Ile) Unlikely pathogenic
c.682G>A p.(Glu228Lys) Pathogenic c.748-2A>G p.(Glu250Glyfs*4) Pathogenic
c.1775G>A p.(Gly592Glu) Pathogenic c.811G>A p.(Val271Ile) Unknown significance
c.662A>G p.(Asp221Gly) Pathogenic c.888C>G p.(Asp296Glu) Unlikely pathogenic
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ogenic variant of LDLRAP1 gene (Table 8).
Seven true homozygous patients were detected; 5 of
them were homozygous for LDLR gene variants and 2 for
LDLRAP1 gene variants. (Table 9).
Finally, one subject was found to carry the APOE gene
variant c.500_502delTCC [p.(Leu167del)], known to be
associated with a dominant FH phenotype.4. Discussion
In this preliminary report we describe the molecular
findings in 1592 patients suspected to have definite or
probable familial hypercholesterolemia identified through
a national collaborative detection program. Only patients
with a Dutch score  6 were admitted to the molecular
investigation program. The exclusion of patients with
Table 9
Homozygous subjects for LDLR and LDLRAP1 gene variants.
LDLR gene variant Protein Clinical
significance
c.1060þ10G>A ? Unknown
significance
c.662A>G p.(Asp221Gly) Pathogenic
c.681C>G p.(Asp227Glu) Pathogenic
c.788A>G p.(Asp263Gly) Pathogenic
c.373C>Tþ(PCSK9
c.60_65dupGCTGCT,
GOF)
p.(Gln125*)þp.(Leu21tri) Pathogenic
LDLRAP1 gene variant Protein Clinical
significance
c.65G>A p.(Trp22*) Pathogenic
c.89-1G p.(Lys30Thrfs*3) Pathogenic
22 A. Pirillo et al. / Atherosclerosis Supplements 29 (2017) 17e24possible FH (Dutch score 3e5) who might be carriers of
pathogenic variants in FH candidate genes [11] was due to
funding limitations, organization problems and to the
deliberate intent to concentrate our efforts on patients who
are more likely to have a monogenic disorder. We used
targeted next generation sequencing which allowed the
parallel sequencing of the major genes known to be
responsible for monogenic forms of hypercholesterolemia.
The overall detection rate of pathogenic/likely patho-
genic variants was around 60%, a figure which is compa-
rable to that obtained in other studies [12,13]. The
assignment of pathogenicity was based on in silico analysis
using several algorithms [4] and information available in
the published variant databases.
In accordance with findings from our previous study [14],
more than 90% of variant-positive patients were carriers of
pathogenic or likely pathogenic variants in the LDLR gene.
Among these patients we discovered 4 true FH homozygotes
carrying known pathogenic variants and 5 patients likely be to
be compound heterozygotes (as they were carriers of two
known pathogenic or likely pathogenic variants of LDLR
gene). In this surveywe discovered 32LDLR genevariants not
reported previously in FH patients. A stringent in silico
analysis [15] indicated that most of these variants can be
assumed to be pathogenic or likely pathogenic.
As previously observed [14], only few patients were
found to be heterozygous carriers of one of the three known
APOB pathogenic variants. None of the patients was found
to be homozygous/compound heterozygous for any of these
variants. However some patients resulted to be double
heterozygous for pathogenic LDLR/APOB variants. Over-
all, these findings confirm that APOB variants are a rare
cause of FH in Italy.
Few patients were found to be heterozygous for putative
pathogenic GOF variants of PCSK9 gene. Surprisingly,
none of them carried one of the three GOF variants reported
previously in Italian FH patients [14] or one of those re-
ported in a recent large survey of FH patients carrying
PCSK9 variants [16]. As a matter of fact, a convincing
demonstration of pathogenicity of one putative GOFvariant found in our FH patients [c.60_65dupGCTGCT
(c.61_63triCTG), p.(Leu21tri)] is not yet available. The
same caution applies also to patients found to be double
heterozygotes for LDLR and PCSK9 variants (Table 6).
Interestingly, most of these double heterozygous patients
(carrying LDLR pathogenic variants) were found to carry
the common polymorphic p.(Arg46Leu) variant, which is
known to have an LDL-C lowering effect in normolipi-
demic as well as in FH patients [17e19].
We sequenced also the LDLRAP1 gene whose patho-
genic variants are the cause of autosomal recessive hyper-
cholesterolemia (ARH), an exceedingly rare disorder in
most countries with exception of the Italian island of Sar-
dinia [7]. Two patients of our series were found to have
ARH due to pathogenic variants of LDLRAP1 while one
patient was found to be double heterozygous for LDLR and
LDLRAP1 pathogenic variants.
This survey included also the sequence of APOE gene,
in the light of previous studies suggesting that some rare
apoE variants might be associated with an FH-like pheno-
type. We found only one patient heterozygous for a known
apoE variant [p.(Leu167del)], considered the cause of FH
with dominant transmission [3]. Recently a large study
conducted in 228 Spanish FH patients in whom the LDLR,
APOB and PCSK9 pathogenic variants had been excluded,
showed that nine patients (3.1%) were carriers of the
p.(Leu167del) variant [20]. This variant was found to
segregate with FH phenotype among index cases’ family
members. In view of these findings, APOE gene should be
included among the genes responsible for FH [21].
This molecular survey paves the way to two main
actions: i) a deep phenotypic analysis of the molecularly
characterized patients, including response to treatment with
hypolipidemic drugs; ii) implementation of the cascade
screening of index patients’ family members to identify
carriers of pathogenic variants and characterize their
phenotype. In view of our previous study, the cascade
screening is expected to lead to the identification of at least
2000 carriers of pathogenic variants who may be unaware
of the burden of having high LDL-C from birth and may
benefit from early treatment and genetic counselling.
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